STATE OF THE ART

Systematic review of randomized controlled trials of therapeutic hypothermia as a neuroprotectant in post cardiac arrest patients

Ka Wai Cheung, MD;* Robert S. Green, BSc, MD;*† Kirk D. Magee, MD, MSc*

ABSTRACT
Objective: Several randomized controlled trials have suggested that mild induced hypothermia may improve neurologic outcome in comatose cardiac arrest survivors. This systematic review of randomized controlled trials was designed to determine if mild induced hypothermia improves neurologic outcome, decreases mortality, or is associated with an increased incidence of adverse events.

Data sources: The following databases were reviewed: Cochrane Controlled Trials Register (Issue 4, 2005), MEDLINE (January 1966 to November 2005), EMBASE (1980 to November 2005), CINAHL (1982 to November 2005) and Web of Science (1989 to November 2005). For each included study, references were reviewed and the primary author contacted to identify any additional studies.

Study selection: Studies that met inclusion criteria were randomized controlled trials of adult patients (>18 years of age) with primary cardiac arrest who remained comatose after return of spontaneous circulation. Patients had to be randomized to mild induced hypothermia (32°C–34°C) or normothermia within 24 hours of presentation. Only studies reporting pre-determined outcomes including discharge neurologic outcome, mortality or significant treatment-related adverse events were included. There were no language or publication restrictions.

Data synthesis: Four studies involving 436 patients, with 232 cooled to a core temperature of 32°C–34°C met inclusion criteria. Pooled data demonstrated that mild hypothermia decreased in-hospital mortality (relative ratio [RR] 0.75; 95% confidence interval [CI], 0.62–0.92) and reduced the incidence of poor neurologic outcome (RR 0.74; 95% CI, 0.62–0.84). Numbers needed to treat were 7 patients to save 1 life, and 5 patients to improve neurologic outcome. There was no evidence of treatment-limiting side effects.

Conclusions: Therapeutically induced mild hypothermia decreases in-hospital mortality and improves neurologic outcome in comatose cardiac arrest survivors. The possibility of treatment-limiting side effects cannot be excluded.

Key words: cardiac arrest; induced hypothermia; systematic review

RÉSUMÉ
Objectif : Plusieurs essais comparatifs randomisés ont suggéré qu’une légère hypothermie provoquée peut améliorer le résultat clinique chez les victimes d’arrêt cardiaque dans le coma. La...
Introduction

Background
Out-of-hospital cardiac arrests are common, with an estimated annual incidence of 36 to 128 per 100 000 people in industrialized countries.\(^1\) It is associated with a 65%–95% mortality rate, and the majority of patients who are resuscitated have a poor neurologic outcome.\(^2–5\) Efforts to identify a treatment modality with a beneficial effect on recovery from anoxic brain injury after cardiac arrest have been disappointing.\(^6–9\) Therapeutic hypothermia may provide beneficial effects for patients who are resuscitated from cardiac arrest by reducing cerebral oxygen demand,\(^10–13\) intracranial pressure,\(^14\) excitatory neurotransmitter production,\(^15\) and oxygen free radical formation/accumulation.\(^16\) However, there has also been concern that mild hypothermia may increase infection rate,\(^17–19\) induce coagulopathy,\(^20,21\) and depress cardiac function.\(^19\)

Importance
Recently, prospective randomized controlled trials have suggested that mild induced hypothermia (core temperature 32°C–34°C) for 12–24 hours may be beneficial in resuscitated post cardiac arrest patients with anoxic brain injury. However, therapeutic hypothermia in cardiac arrest survivors remains controversial due to the relatively small number of total study patients, low enrolment of eligible patients and a perceived difficulty in applying this mode of therapy.

Objectives
This systematic review will assess whether mild induced hypothermia decreases mortality and improves neurologic outcomes in comatose survivors resuscitated from cardiac arrest. Furthermore, we will also determine whether mild hypothermia in this setting causes significant adverse events.

Methods
Data source
A comprehensive search of the Cochrane Controlled Trials Register (Issue 4, 2005), MEDLINE (January 1966 to November 2005), EMBASE (1989 to November 2005), CINAHL (1982 to November 2005), and Web of Science (1989 to November 2005) was conducted to identify studies. There were no language or publication restrictions. The search consisted of the following terms: cardiac arrest, heart arrest, cardiopulmonary resuscitation, hypothermia, and induced hypothermia. Reference lists of included studies were also examined for additional eligible studies.
all available primary studies and review articles were assessed to identify potentially relevant citations. Inquiries regarding other published or unpublished studies known and/or supported by the authors of the included studies were performed. In addition, personal contact with colleagues, collaborators and other investigators working in the field of hypothermia in cardiac arrest survivors was made to identify potentially relevant studies.

All trials that appeared relevant on the basis of “Title,” “Abstract” or “MeSH Headings” were selected for full review by one reviewer (K.W.C.). From these potentially relevant articles and using an inclusion and exclusion criteria checklist, 2 reviewers (K.W.C. and R.G.) independently selected trials based on the full text for inclusion into the review. Agreement was measured using simple agreement and kappa statistics. Disagreement was resolved by consensus or third party adjudication.

**Study selection**

Inclusion criteria were any study that was a randomized or quasi-randomized controlled clinical trial of adults (>18 years of age) who had a primary cardiac arrest and were comatose (Glasgow Coma Scale score <8) after return of spontaneous circulation (ROSC). Other inclusion criteria included patient randomization to mild induced hypothermia (32°C–34°C) versus normothermia within 24 hours of presentation and assessment and description of neurologic outcome or mortality.

**Validity assessment**

Two reviewers (K.W.C., K.M.) who were unblinded to authors and study results independently assessed methodological quality of each included study by using 2 methods: the Cochrane concealment of allocation approach and the Jadad criteria. The Cochrane approach assesses allocation concealment using the following principles: grade A – adequate concealment, grade B – uncertain concealment, and grade C – clearly inadequate concealment. In addition, each study was assessed using a previously validated 0–5 scale described by Jadad. The Jadad Scale determines the quality of clinical trials based on study randomization, presence of double-blinding, the description of withdrawals and the process of randomization and blinding.

**Data abstraction**

A priori outcomes included in-hospital mortality, 6-month mortality, discharge neurologic outcome, as well as hemodynamic instability, dysrhythmia, infection or sepsis, and coagulopathy. “Good” neurologic outcome was defined as either no disability or mild-to-moderate disability, and “poor” neurologic outcome included those with more severe disability. Data from all included studies were extracted by one reviewer (K.W.C.) and double entered to ensure data accuracy into Review Manager (Version 4.1; Oxford, UK).

**Quantitative data synthesis**

For dichotomous variables, individual and pooled statistics were calculated as relative risks (RRs) with 95% confidence intervals (95% CIs). For continuous outcomes, individual and pooled statistics were calculated as weighted mean differences or standardized mean differences with 95% CIs. A random effects model was to be used if more than 5 trials were pooled. When fewer trials or no heterogeneity was identified, a fixed effects model was employed. Random effects modelling takes into account both within-study variability and between-study variation, and fixed effect modelling assumes that all variance come from within-study.

Heterogeneity refers to the differences in results of the individual studies included in the systematic review. Heterogeneity was assessed using the I^2 statistic and the Breslow–Day χ^2 test with significance denoted by a p value <0.10. In the setting of significant heterogeneity, it was decided a priori to conduct a sensitivity analysis with the groups being divided based on methodological quality. Those studies with a Jadad Scale score of ≥3 were to be compared with those with a score <3. Although extensive efforts were made to identify unpublished studies, funnel plots were analyzed for evidence of publication bias.

**Results**

**Selection of studies**

In total, 2131 potentially relevant articles were screened for retrieval. Forty-seven articles (or abstracts, when full articles were unavailable) were retrieved and reviewed independently by 2 investigators (K.W.C., R.G.). This first review yielded 4 studies that met inclusion criteria. The agreement kappa statistic for study inclusion was good (κ = 0.85). A review of the reference lists of these selected articles yielded 1 potentially relevant article. However, this last article was subsequently excluded as not all patients had ROSC. After contacting the authors of all the included studies, no further relevant studies were identified, resulting in 4 studies of 436 patients being included in the review (Fig. 1). The funnel plot demonstrates asymmetry in the area of small negative trials, indicating that unpublished negative trials might exist that we failed to identify for inclusion in this review.
Study characteristics

Table 1 summarizes the 4 included studies. The Hypothermia after Cardiac Arrest (HACA) Study\(^{30}\) and the Bernard and colleagues study\(^{31}\) were large multicentre trials, and the Hachimi-Idrissi and coworkers\(^{29}\) and Mori and associates\(^{28}\) studies were smaller, single-centre trials. The Hachimi-Idrissi and coworkers study was a feasibility study: once mild hypothermia was attained, the cooling helmet was removed. The inclusion criteria for presenting cardiac rhythms differed between the trials; the HACA Study\(^{30}\) and Bernard and colleagues study\(^{31}\) included only patients presenting with ventricular arrhythmias, while Hachimi-Idrissi and coworkers enrolled only patients presenting with asystole or pulseless electrical activity (PEA). The initial rhythm was unclear in patients enrolled in the Mori and associates study. Greater than 94% of included patients had a witnessed cardiac arrest in the HACA and Bernard and colleagues studies, and only approximately 50% of patients had a witnessed cardiac arrest in the Hachimi-Idrissi and coworkers study. The median time from collapse to ROSC ranged from 21 to 34 minutes in the 3 trials reporting this variable.

There was dichotomy in the methodologic quality of the included studies. Two studies had adequate concealment of allocation with Jadad Scale scores of 3 (Table 2). In the other 2 studies, concealment of allocation was unclear or inadequate. Both of these studies had Jadad scores of 1.

Sensitivity analyses

Three studies reported in-hospital mortality\(^{29–31}\). Only 1 of these studies showed a definite decrease in in-hospital mortality.\(^{30}\) However, when data from the 3 studies were pooled, mild induced hypothermia reduced the overall incidence of in-hospital mortality compared with treatment with normothermia (RR, 0.75; 95% CI, 0.62–0.92). No significant heterogeneity was identified ($p = 0.56; I^2 = 0\%$). Seven (95% CI, 4–25) patients would require treatment with mild induced hypothermia to prevent 1 in-hospital death (Fig. 2).

All 4 studies reported neurologic outcome, and 3 of the 4 showed improved neurologic outcomes with mild hypothermia.\(^{28,30,31}\) Although different assessment scales were used in the trials, patients classified as having “good” neurologic outcomes were similar between studies. The HACA Study\(^{30}\) and the Hachimi-Idrissi and coworkers study\(^{29}\) used the Glasgow–Pittsburgh Cerebral Performance category to determine neurologic status. Good neurologic outcome was defined as 1 (good recovery) or 2 (moderate disability), and poor outcome was defined as a Cerebral Performance Category of 3 (severe disability), 4 (vegetative state) or 5 (death). Mori and associates\(^{29}\) used the Glasgow Outcome Scale, with good neurologic outcome being moderate, mild, or no disability. The Bernard and colleagues study\(^{31}\) assessed outcome based on discharge loca-
and the Canadian Association of Emergency Physicians Critical Care Committee\textsuperscript{13-35} have recommended mild hypothermia be considered for select cardiac arrest patients who are comatose after ROSC. Others have recommended the earliest possible initiation of cooling after ROSC, and some data suggests that pre-hospital cooling is feasible.

Despite these recommendations, a recent survey\textsuperscript{36} of practising US emergency physicians, critical care physicians and cardiologists showed that 87% of respondents had never used hypothermia following cardiac arrest. The main reasons cited for not inducing mild hypothermia were insufficient data, treatment not mentioned in Advanced Cardiac Life Support protocols and technical difficulties related to cooling. As the HACA Study\textsuperscript{30} only en-

Table 1. Comparison of the 4 randomized controlled trials included in the systematic review

<table>
<thead>
<tr>
<th>Study (total no. of patients)</th>
<th>Presenting cardiac rhythm</th>
<th>Hypothermia group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Method of cooling</td>
<td>Goal temp</td>
<td>Time to goal temp</td>
</tr>
<tr>
<td>HACA Group\textsuperscript{30} (n = 275)</td>
<td>VF or pulseless VT</td>
<td>Cooling mattress (plus ice packs as needed)</td>
<td>Bladder temp 32°C–34°C ≤ 4 h after ROSC</td>
</tr>
<tr>
<td>Bernard et al\textsuperscript{31} (n = 77)</td>
<td>VF</td>
<td>Ice packs</td>
<td>Tympanic/bladder temp 33°C ≤ 2 h after ROSC</td>
</tr>
<tr>
<td>Hachimi-Idrissi et al\textsuperscript{29} (n = 30)</td>
<td>Asystole or PEA</td>
<td>Cooling helmet</td>
<td>Bladder temp 34°C ≤ 4 h after initial cooling</td>
</tr>
<tr>
<td>Mori et al\textsuperscript{28} (n = 54)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>32°C–34°C</td>
</tr>
</tbody>
</table>

Note: In the HACA Study, 2 patients were lost to follow-up. temp = temperature; VF = ventricular fibrillation; VT = ventricular tachycardia; PEA = pulseless electrical activity; ROSC = return of spontaneous circulation

**Table 2. Methodologic quality assessment of the 4 studies included in the review**

<table>
<thead>
<tr>
<th>Study</th>
<th>Jadad Scale score*</th>
<th>Cochrane grade†</th>
</tr>
</thead>
<tbody>
<tr>
<td>HACA Group\textsuperscript{30}</td>
<td>3</td>
<td>A</td>
</tr>
<tr>
<td>Bernard et al\textsuperscript{31}</td>
<td>1</td>
<td>C</td>
</tr>
<tr>
<td>Hachimi-Idrissi et al\textsuperscript{29}</td>
<td>3</td>
<td>A</td>
</tr>
<tr>
<td>Mori et al\textsuperscript{28}</td>
<td>1</td>
<td>B</td>
</tr>
</tbody>
</table>

*Jadad Scale (0–5) determines quality of clinical trials based on study randomization, presence of double-blinding, description of withdrawals and process of randomization and blinding.\textsuperscript{24}
†Cochrane approach assesses allocation concealment using the following principles: grade A, adequate concealment; B, uncertain concealment; C, clearly inadequate concealment.\textsuperscript{23}

**Discussion**

The International Liaison Committee on Resuscitation\textsuperscript{32} and the American Heart Association\textsuperscript{33–35} have recommended mild hypothermia be considered for select cardiac arrest patients who are comatose after ROSC. Others have recommended the earliest possible initiation of cooling after ROSC, and some data suggests that pre-hospital cooling is feasible.

Despite these recommendations, a recent survey\textsuperscript{36} of practising US emergency physicians, critical care physicians and cardiologists showed that 87% of respondents had never used hypothermia following cardiac arrest. The main reasons cited for not inducing mild hypothermia were insufficient data, treatment not mentioned in Advanced Cardiac Life Support protocols and technical difficulties related to cooling. As the HACA Study\textsuperscript{30} only en-
rolled 8% of their patients initially assessed for study eligibility, the generalizability of mild hypothermia to all patients with cardiac arrest has also been questioned. This systematic review sought to compile data from all relevant literature concerning the use of mild hypothermia in comatose post cardiac arrest survivors. Despite differences in cooling protocols between the studies, the pooled results demonstrate that mild hypothermia is associated with statistically significant and clinically important decreases in hospital mortality and improvements in neurologic outcome. Mild hypothermia was also successfully induced within 2–6 hours of external cooling in the 3 studies which reported this variable. Although not uniformly reported across all studies, mild hypothermia did not significantly increase adverse events. As with any systematic review, the reported incidence of side effects must be viewed with caution.

Clearly, sudden cardiac arrest is common and carries a dismal prognosis. In those patients for whom resuscitation is attempted, less than 10% survive to hospital discharge, and less than 50% of discharged patients are neurologically intact. Brain death or limitation of active treatment is often the cause of patient demise. Currently, the standard of care for primary cardiac arrest patients who remain comatose after ROSC involves supportive care and serial neurologic examination to determine prognosis.

The pathophysiology of ischemic neuronal injury is incompletely understood but is thought to occur through a myriad of mechanisms, including release of excitatory neurotransmitters, dysregulation of calcium homeostasis, and free radical oxidation of cellular components. Anoxic brain injury, although related to the length of no circulation time, is an ongoing process after ROSC, decreasing metabolic demand, decreasing the release of excitatory neurotransmitters, and decreasing inflammation.

Animal studies since the 1980s have suggested that mild induced hypothermia may be beneficial as a neuroprotectant after cardiac arrest. In addition, human literature describes a beneficial effect of mild induced hypothermia in resuscitated post cardiac arrest patients. However, there is concern that core temperature reduction may be associated with increased rates of hemodynamic instability, coagulopathy, and immune deficiency, therefore resulting in increased rates of sepsis and pneumonia.

Multiple complications were assessed by the included studies, and there was no adverse event consistently associ...
ated with hypothermia. The Bernard and colleagues study\textsuperscript{31} demonstrated a statistically significant increase in the incidence of hyperglycemia in the hypothermia group. Although hyperglycemia has been suggested to cause additional neurologic damage in a carotid artery occlusion study on rats,\textsuperscript{61} this was not the case in the Bernard and colleagues study. In the Hachimi-Idrissi and coworkers study,\textsuperscript{29} enrolled patients had either PEA or asystolic arrest, and the majority did not survive. It is possible that these patients did not live long enough to develop complications associated with hypothermia treatment. However, patients in the hypothermia group did have lower $\text{O}_2$ extraction ratios and lower lactate levels. This has been seen in multiple other hypothermia studies,\textsuperscript{10,11,47,62} indicating that at least some commonly seen effects of hypothermia were present, despite the short duration of cooling. No specific biochemical aberrations were demonstrated in this study.

**Limitations**

This systematic review is a comprehensive analysis of the available literature. However, the results are dominated by the HACA Study\textsuperscript{30} due to the large number of patients enrolled. The Bernard and colleagues,\textsuperscript{31} HACA, and Mori and associates\textsuperscript{28} studies all showed improved neurologic outcome with mild hypothermia. However, the HACA Study was the only one that showed a statistically significant decrease in mortality. Furthermore, differences in cooling procedures and duration limit our ability to comment on the optimal method, rate and duration of induced hypothermia. There are inadequate data to comment on potential rates of complications with mild hypothermia. Finally, the 2 largest studies in this review only included patients with unstable ventricular arrhythmias.

There is a possibility of publication bias in this review. By missing unpublished “statistically” negative trials, it is possible to overestimate the treatment effect; however, a comprehensive search of the published literature for potentially relevant studies was conducted, using a systematic strategy to avoid bias. This was followed by contacts with corresponding and first authors. Although no unpublished or negative trials were identified, we recognize that these types of trials may exist. In addition, the funnel plot demonstrates asymmetry, its capacity to detect bias is limited when only a limited number of small trials are included in a meta-analyses. Given the nature of this research (e.g., expensive, complex, difficult to fund), these small negative trials are unlikely and would not be expected to influence the results.

There is also the possibility of study selection bias. However, we employed 2 independent reviewers and feel confident that the studies excluded were done so for consistent and appropriate reasons. Our search was comprehensive and has been updated, so it is unlikely that we missed any published trials.

With respect to the pooling of data, “moderate” heterogeneity was identified for neurologic outcome. However, the $\chi^2$ test for heterogeneity was not statistically significant. Although the trials included in this systematic review differ somewhat, they are sufficiently similar in their populations studied, interventions, outcomes and design to warrant pooling of data. Visual inspection of the Forrest plot for neurologic outcome (Fig. 3) reveals that all of the 95% CIs of the individual trials overlap and that the point estimates all favour treatment, making for “visual homogeneity.”

This review demonstrates a clinically significant improvement in neurologic outcome and decrease in mortality in post cardiac arrest comatose patients treated with mild hypothermia. The findings of a recent individual patient data meta-analysis on induced hypothermia after cardiac arrest also showed a benefit of mild hypothermia on neurologic outcome and mortality.\textsuperscript{63} The study by Mori and associates,\textsuperscript{28} which met their inclusion criteria but was only available in abstract form, was not included. Further research is required to determine which patients will receive the greatest benefit from mild hypothermia as the discussed studies included patients with varying presenting cardiac rhythms. The optimal method and duration of inducing hypothermia are yet to be determined. Finally, legitimate concerns regarding the incidence of treatment limiting side-effects such as sepsis and hemorrhage require further investigation.

**Competing interests:** None declared.

**Acknowledgements:** We thank Mr. Tim Ruggles for assistance with the literature search. We also acknowledge the assistance of the following authors of included studies: F. Sterz, S.A. Bernard, S. Hachimi-Idrissi, E. Dickson, and K. Mori. We also thank Dr. Brian Rowe, Canada Research Chair in Emergency Airway Diseases and Research Director, Department of Emergency Medicine, University of Alberta, for his advice on the manuscript.

**References**


Correspondence to: Dr. Robert Green, Division of Critical Care, Queen Elizabeth II Health Sciences Centre, Dalhousie University, 1278 Tower Rd., Rm. 349, Bethune Building, Halifax NS B3H 2Y9